Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us ![]()
About
PEGS Boston SummitPEGS Boston Summit
Not Confirmed
Not Confirmed
11 May-15 November, 2026
Not Confirmed
Not Confirmed
07-10 June, 2026
Not Confirmed
Not Confirmed
09-11 June, 2026
List your booth number for exhibitions, ask us
CONTACT DETAILS




Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
PEGS Boston SummitPEGS Boston Summit
Industry Trade Show
Not Confirmed
11 May-15 November, 2026
Industry Trade Show
Not Confirmed
07-10 June, 2026
Industry Trade Show
Not Confirmed
09-11 June, 2026
Digital content

21 Apr 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260421480755/en/Synthekine-Presents-Updated-Clinical-and-Translational-Data-Demonstrating-Strong-Activity-for-STK012-in-FirstLine-NonSquamous-NSCLC-in-Oral-Presentation-at-AACR-2026

17 Mar 2026
// BUSSINESSWIRE
https://www.businesswire.com/news/home/20260317549668/en/Synthekine-Announces-AACR-2026-Oral-Presentation-of-Updated-Phase-1a1b-Clinical-and-Translational-Data-for-STK012-in-FirstLine-Nonsquamous-NSCLC-with-Features-of-Immunotherapy-Resistance

26 Feb 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260226901519/en/Synthekine-Announces-Clinical-Trial-Collaboration-with-Merck-to-Evaluate-STK-012-In-Combination-with-Keytruda-Pembrolizumab-and-Chemotherapy-in-Ongoing-Randomized-Phase-2-Trial-in-First-Line-PD-L1-Negative-Nonsquamous-Non-Small-Cell-Lung-Cancer

23 Feb 2026
// PHARMIWEB
https://www.pharmiweb.com/press-release/2026-02-23/synthekine-appoints-biotechnology-and-pharmaceutical-industry-veteran-john-a-orwin-as-chair-of-its

13 Nov 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251113131381/en/First-Patient-Dosed-in-SYNERGY-101-a-Global-Randomized-Phase-2-Clinical-Trial-of-STK-012-in-First-Line-PD-L1-Negative-Nonsquamous-Non-Small-Cell-Lung-Cancer

07 Nov 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251107945337/en/Synthekine-Presents-Positive-Initial-Results-from-Phase-1a1b-Clinical-Trial-of-STK-012-Plus-Pembrolizumab-and-Chemotherapy-in-First-Line-PD-L1-Negative-Nonsquamous-Non-Small-Cell-Lung-Cancer
ABOUT THIS PAGE